Agentic AI in Clinical Trials Moves Beyond Insights Toward Workflow Automation

Artificial intelligence in clinical trials is moving beyond data analysis and prediction toward systems that can perform defined tasks within clinical development workflows. The next phase focuses on how AI agents can retrieve evidence, compare records, identify discrepancies, and support clinical teams while keeping important decisions under human control.

In an October 19, 2026, sponsored episode of The Top Line podcast, Saama leaders Ari Srinivasan, Chief Customer Success and Growth Officer, and Yatesh Midha, Associate Vice President of Product Management, discussed this shift and the role of the company's AgentOS platform.

Explore Clinical Trials Market PDF Including Complete Dataset, Company Quadrant, GTM Strategies, Buyer Identification and More: https://www.towardshealthcare.com/download-sample/5029 

From Predictive Models to Agentic AI

Earlier applications of AI helped clinical research teams predict operational risks, identify data-quality problems, and recognize potential delays. Generative AI expanded these capabilities by helping users explore complex information and understand large volumes of clinical data.

Agentic AI introduces another possibility. Instead of only generating insights or answering questions, AI agents can carry out specific tasks across defined workflows, subject to permissions and oversight.

For clinical research organizations, this could mean less time spent comparing records manually and more time investigating exceptions, reviewing evidence, and making decisions that require professional judgment.

How AgentOS Could Support Clinical Workflows

Saama's AgentOS is presented as an orchestration and governance layer that connects specialized tools, skills, AI agents, and workflows. Rather than relying on one general-purpose model for every task, this approach allows different agents to handle specific responsibilities within a controlled system.

For example, an agent could retrieve relevant evidence from clinical systems, compare information across records, and flag inconsistencies for review. The system could help teams identify missing information or conflicting entries without automatically deciding which clinical record is correct.

This distinction is important because clinical data often passes through multiple systems and teams. A structured workflow can help professionals trace the information behind a finding and determine what needs further investigation.

Why Human Oversight Remains Essential

Clinical trials operate under strict requirements for data integrity, patient safety, documentation, and regulatory compliance. An AI-generated answer is not sufficient unless teams can understand where the information came from and verify its accuracy.

Saama's approach emphasizes task-appropriate models, evidence-grounded outputs, traceable information sources, permission controls, and human responsibility for consequential decisions.

These safeguards matter because an incorrect data reconciliation or an unsupported conclusion could create additional review work or affect downstream trial activities. AI agents should therefore operate within clearly defined boundaries, with appropriate escalation procedures and documented human review.

What Clinical Research Leaders Should Evaluate

For pharmaceutical companies, biotechnology developers, and contract research organizations, the opportunity extends beyond adopting a new AI tool. Leaders need to determine whether the technology can improve specific workflows without compromising data quality or oversight.

Important evaluation areas include:

• Workflow efficiency: Can AI reduce repetitive data comparison and evidence retrieval?

• Data traceability: Can users verify the sources behind every important finding?

• System integration: Can agents work across existing clinical platforms without creating conflicting records?

• Governance: Are access permissions, audit trails, and escalation procedures clearly defined?

• Human review: Can clinical professionals validate discrepancies and retain responsibility for important decisions?

Organizations should measure performance against established baselines, including review time, discrepancy resolution, error rates, and the amount of human rework required. These measurements can help distinguish practical improvements from unverified claims about AI capabilities.

The Next Stage of AI in Clinical Development

Agentic AI could help clinical teams move away from repetitive administrative tasks and focus more attention on complex exceptions, evidence assessment, and operational decisions. However, its value will depend on reliable integrations, transparent outputs, effective governance, and measurable results in real clinical workflows.

The central question for the industry is no longer simply whether AI can analyze clinical data. It is whether AI agents can complete clearly defined tasks reliably, with the right controls and human oversight.

For clinical development leaders, the next phase will require evaluating AI not just by what it can generate, but by how safely and consistently it can support the work required to deliver clinical trials.

About Us

Healthcare WebWire is part of Towards Healthcare, which is a healthcare intelligence and market research company specializing in market intelligence, competitive intelligence, customer intelligence, pipeline intelligence, market sizing and commercial strategy across pharmaceutical, biotechnology, medical device and healthcare markets.

Contact us for quick meeting, customized data, free samples or further enquiry at [email protected]

Europe Region - +44 778 256 0738

North America Region - +1 8044 4193 44

APAC Region: +91 9356 9282 04

Visit Our Website: https://www.towardshealthcare.com

Find us on social platforms: LinkedIn | Twitter | Instagram | Medium